Anti-PD-L1 Antibodies
AssigneeAgency for Science, Technology and Research
InventorsCheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
Life of this patent
Estimating the term…
Abstract
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
Claims20
A method of treating cancer, comprising administering an antibody or antigen binding fragment to a patient suffering from a cancer, wherein the antibody or antigen binding fragment binds to PD-L1, and comprises:
- at least one light chain variable region incorporating the following CDRs:
- LC-CDR1 :
- (SEQ ID NO:
- 18)
- TGSSSNIGAGYDVH
- LC-CDR2:
- (SEQ ID NO:
- 19)
- GNSNRPS
- LC-CDR3:
- (SEQ ID NO:
- 20)
- QSYDSSLSGSYVV;
- and
- at least one heavy chain variable region incorporating the following CDRs:
- HC-CDR1:
- (SEQ ID NO:
- 21)
- SYAIS
- HC-CDR2:
- (SEQ ID NO:
- 22)
- RIIPILGIANYAQKFQG
- HC-CDR3:
- (SEQ ID NO:
- 25)
- SGHGYSYGAFDY.
A method of treating cancer, comprising administering an antibody or antigen binding fragment to a patient suffering from a cancer, wherein the antibody or antigen binding fragment binds to PD-L1, and comprises:
- a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8 or 35, and
- the light chain variable region comprising the amino acid sequence of SEQ ID NO:4.
A method of treating cancer in a subject, comprising:
- culturing T cells obtained from a blood sample from a subject having a cancer in the presence of an antibody or antigen binding fragment which binds to PD-L1 to expand a T cell population;
- and
- administering the expanded T cell population to the subject;
- wherein the antibody or antigen binding fragment which binds to PD-L1 comprises:
- at least one light chain variable region incorporating the following CDRs:
- LC-CDR1:
- (SEQ ID NO:
- 18)
- TGSSSNIGAGYDVH
- LC-CDR2:
- (SEQ ID NO:
- 19)
- GNSNRPS
- LC-CDR3:
- (SEQ ID NO:
- 20)
- QSYDSSLSGSYVV;
- and
- at least one heavy chain variable region incorporating the following CDRs:
- HC-CDR1:
- (SEQ ID NO:
- 21)
- SYAIS
- HC-CDR2:
- (SEQ ID NO:
- 22)
- RIIPILGIANYAQKFQG
- HC-CDR3:
- (SEQ ID NO:
- 25)
- SGHGYSYGAFDY.
Dependencies are inferred from the claim text.